Rare Hematology News
Advertisement
Disease Profile
Paraneoplastic Neurologic Disorders
Prevalence estimates on Rare Medical Network websites are calculated based on data available from numerous sources, including US and European government statistics, the NIH, Orphanet, and published epidemiologic studies. Rare disease population data is recognized to be highly variable, and based on a wide variety of source data and methodologies, so the prevalence data on this site should be assumed to be estimated and cannot be considered to be absolutely correct.
#N/A
Age of onset
#N/A
ICD-10
#N/A
Inheritance
Autosomal dominant A pathogenic variant in only one gene copy in each cell is sufficient to cause an autosomal dominant disease.
Autosomal recessive Pathogenic variants in both copies of each gene of the chromosome are needed to cause an autosomal recessive disease and observe the mutant phenotype.
X-linked
dominant X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
dominant X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
X-linked
recessive Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder.
recessive Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder.
Mitochondrial or multigenic Mitochondrial genetic disorders can be caused by changes (mutations) in either the mitochondrial DNA or nuclear DNA that lead to dysfunction of the mitochondria and inadequate production of energy.
Multigenic or multifactor Inheritance involving many factors, of which at least one is genetic but none is of overwhelming importance, as in the causation of a disease by multiple genetic and environmental factors.
Not applicable
Other names (AKA)
PND
Categories
Hereditary Cancer Syndromes
Summary
Paraneoplastic neurologic disorders are a group of rare degenerative conditions that are triggered by a person's
Organizations
Support and advocacy groups can help you connect with other patients and families, and they can provide valuable services. Many develop patient-centered information and are the driving force behind research for better treatments and possible cures. They can direct you to research, resources, and services. Many organizations also have experts who serve as medical advisors or provide lists of doctors/clinics. Visit the group’s website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.
Organizations Supporting this Disease
-
International Autoimmune Encephalitis Society
Telephone: 352-527-2470
E-mail: [email protected]
Website: https://autoimmune-encephalitis.org/
Social Networking Websites
- The International Autoimmune Encephalitis Society Facebook group offers educational support through this forum.
-
RareConnect has an online community for patients and families with this condition so they can connect with others and share their experiences living with a rare disease. The project is a joint collaboration between EURORDIS (European Rare Disease Organisation) and NORD (National Organization for Rare Disorders).
Organizations Providing General Support
-
American Autoimmune Related Diseases Association (AARDA)
19176 Hall Road, Suite 130
Clinton Township, MI 48038
Toll-free: 800-598-4668
Telephone: 586-776-3900
Fax: 586-776-3903
E-mail: [email protected]
Website: https://www.aarda.org/ -
American Cancer Society
250 Williams Street NW
Atlanta, GA 30329
Toll-free: 1-800-227-2345
Website: https://www.cancer.org
Learn more
These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.
Where to Start
- The International Autoimmune Encephalitis Society offers patients and families detailed information on diagnosis and treatment.
- The National Institute of Neurological Disorders and Stroke (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on this topic.
- The National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.
In-Depth Information
- Medscape Reference provides information on this topic. You may need to register to view the medical textbook, but registration is free.
Selected Full-Text Journal Articles
- Binks SNM, Klein CJ, Waters P, Pittock SJ, Irani SR. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry. 2018 May;89(5):526-534.
- McKeonA. Paraneoplastic and other autoimmune disorders of the central nervous system. Neurohospitalist. 2013 Apr; 3(2):53-64.
- Jammoul A, Li Y, Rae-Grant A. Autoantibody-mediated encephalitis: Not just paraneoplastic, not just limbic, and not untreatable. Cleveland Clinic Journal of Medicine. 2016 January;83(1):43-53.
References
- NINDS Paraneoplastic Syndromes Information Page. National Institute of Neurological Disorders and Stroke Website. March 12, 2009; https://www.ninds.nih.gov/Disorders/All-Disorders/Paraneoplastic-Syndromes-Information-Page. Accessed 6/9/2016.
- Josep Dalmau, Myrna R Rosenfeld. Overview of paraneoplastic syndromes of the nervous system. UpToDate. October 5, 2015; https://www.uptodate.com/contents/overview-of-paraneoplastic-syndromes-of-the-nervous-system.
- Sudheeran Kannoth. Paraneoplastic neurologic syndrome: A practical approach. Annals of Indian Academy of Neurology. Jan-Mar 2012; 15(1):6-12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299076/.
- Dalmau J, Rosenfeld M. Paraneoplastic neurologic syndromes. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Abeloff's Clinical Oncology, 4th ed. Philadelphia: Churchill Livingstone; 2008; 767-778.